A Study of LY3454738 in Adults With Chronic Spontaneous Urticaria

Summary

The reason for this study is to see if the study drug LY3454738 is safe and effective as treatment for participants with hives that are caused by chronic spontaneous urticaria (CSU) and that are not controlled with H1-antihistamines.

Timeline

Start

2019-11-15

Primary completion

2021-02-24

Completion

2021-02-24

Outcome

Missed primary endpoint

Stopped: “The study was terminated for lack of efficacy after an interim analysis was performed”

registry analysis (superiority test); Sequence Group 1: (500 mg LY3454738, Placebo) vs Sequence Group 2: (Placebo, 500 mg LY3454738); p = 0.380 NCT04159701 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	UCENPRUBART	Monoclonal antibody	500 mg	Intravenous

Indications